Thermo Fisher Scientific Inc. (TMO) SEC Filings & Earnings Calls
EquiReason read 14 Thermo Fisher Scientific Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Revenue grew 9% to $12.14B, GAAP EPS $4.64 (+9%), adjusted EPS $6.68 (+15%), organic growth 6%. Guidance update deferred to call..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 249.1B
- P/E TTM
- 36.2
- Dividend yield
- 0.3%
- 52-week
- —
- Next earnings
- 27 Jan, in 94 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Oct 20268-K · 2.02Revenue grew 9% to $12.14B, GAAP EPS $4.64 (+9%), adjusted EPS $6.68 (+15%), organic growth 6%. Guidance update deferred to call.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2026 | $12.14B | +9% y/y |
| GAAP diluted EPS · Q3-2026 | $4.64 | +9% y/y |
| Adjusted EPS · Q3-2026 | $6.68 | +15% y/y |
| GAAP operating income · Q3-2026 | $2.26B | +17% y/y |
| Adjusted operating income · Q3-2026 | $2.97B | +15% y/y |
| GAAP operating margin · Q3-2026 | 18.6% | |
| Adjusted operating margin · Q3-2026 | 24.5% |
Risks flagged
No material risk signals in this earnings release; guidance deferred to call
“Guidance update deferred to earnings call; no explicit forward-looking numbers provided”
31 Jul 202610-QThermo Fisher reported strong Q2 2026 results with revenue up 10% YoY and adjusted EPS up 13%, driven by broad-based growth and margin expansion.earningsopen
Figures in the filing · each found in the filing text
| Revenues · Q2-2026 | $11.99B | +10% y/y |
| GAAP operating income · Q2-2026 | $2.09B | +14% y/y |
| GAAP operating income margin · Q2-2026 | 17.4% | |
| Adjusted operating income margin · Q2-2026 | 22.8% | |
| GAAP diluted earnings per share · Q2-2026 | $4.68 | +9% y/y |
| Adjusted earnings per share · Q2-2026 | $6.03 | +13% y/y |
| Organic revenue growth · Q2-2026 | 5.0% | |
| Free cash flow · H1-2026 | $2.50B | +69% y/y |
| Net cash provided by operating activities · H1-2026 | $3.32B | +56% y/y |
| Life Sciences Solutions revenue · Life Sciences Solutions · Q2-2026 | $2.81B | +13% y/y |
Risks flagged
Integration risk from Clario acquisition
“On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider of endpoint data solutions for clinical trials.” · word for word
Increased debt from acquisitions and share repurchases
“Total debt 42,549 39,384” · word for word
23 Jul 20268-K · 2.02Revenue $11.99B (+10% y/y); GAAP diluted EPS $4.68 (+9% y/y); Adjusted EPS $6.03 (+13% y/y)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $11.99B | +10% y/y |
| GAAP diluted EPS · Q2-2026 | $4.68 | +9% y/y |
| Adjusted EPS · Q2-2026 | $6.03 | +13% y/y |
| GAAP operating income · Q2-2026 | $2.09B | +14% y/y |
| Adjusted operating income · Q2-2026 | $2.73B | +15% y/y |
| GAAP operating margin · Q2-2026 | 17.4% | |
| Adjusted operating margin · Q2-2026 | 22.8% |
Risks flagged
Exposure to global economic and geopolitical risks
“Forward-looking statements reference risks including global economic conditions, supply chain, and geopolitical developments”
1 May 202610-QRevenue $11.01B (+6% y/y); GAAP operating income $1.86B (+9% y/y); Adjusted operating income $2.40B (+6% y/y); Guidance: FY2026 capex guided $1.9B-$2.1B; GAAP tax rate 9%-11%; adjusted tax rate ~11.5%open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $11.01B | +6% y/y |
| GAAP operating income · Q1-2026 | $1.86B | +9% y/y |
| Adjusted operating income · Q1-2026 | $2.40B | +6% y/y |
| Adjusted EPS · Q1-2026 | $5.44 | +6% y/y |
| Free cash flow · Q1-2026 | $825M | +121% y/y |
| Organic revenue growth · Q1-2026 | 1.0% | |
| Life Sciences Solutions revenue · Life Sciences Solutions · Q1-2026 | $2.64B | +13% y/y |
| Analytical Instruments revenue · Analytical Instruments · Q1-2026 | $1.72B | 0% y/y |
| Specialty Diagnostics revenue · Specialty Diagnostics · Q1-2026 | $1.14B | -1% y/y |
| Laboratory Products and Biopharma Services revenue · Laboratory Products and Biopharma Services · Q1-2026 | $6.04B | +7% y/y |
Guidance
FY2026 capex guided $1.9B-$2.1B; GAAP tax rate 9%-11%; adjusted tax rate ~11.5%
Company reaffirms full-year capex guidance of $1.9B-$2.1B and tax rate guidance, with no explicit revenue guidance change
Risks flagged
Tariff and FX margin pressure
“The decrease in segment income margin was driven by the impacts of tariffs and related foreign exchange, unfavorable business mix, and lower volume” · word for word
Academic/government demand weakness
“Revenues in the academic and government market declined, driven by muted macro conditions in the U.S. and China.” · word for word
High debt from acquisitions
“Total debt $43,161 million as of March 28, 2026, up from $39,384 million at year-end 2025”
23 Apr 20268-K · 2.02Revenue $11.01B (+6% y/y); GAAP diluted earnings per share $4.43 (+11% y/y); Adjusted earnings per share $5.44 (+6% y/y)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $11.01B | +6% y/y |
| GAAP diluted earnings per share · Q1-2026 | $4.43 | +11% y/y |
| Adjusted earnings per share · Q1-2026 | $5.44 | +6% y/y |
| GAAP operating income · Q1-2026 | $1.86B | +9% y/y |
| Adjusted operating income · Q1-2026 | $2.40B | +6% y/y |
Risks flagged
Organic revenue growth only 1%, indicating potential slowdown in core business.
“Organic revenue growth was 1%.” · word for word
Adjusted operating margin slightly declined YoY.
“Adjusted operating margin was 21.8%, compared with 21.9% in the first quarter of 2025.” · word for word
7 Apr 2026DEF 14AProxy statement disclosing 2025 compensation, governance, and shareholder engagement, including a significant CEO retention grant and compensation program changes.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $44.56B | +4% y/y |
| GAAP Diluted EPS · FY2025 | $17.74 | +7% y/y |
| Adjusted EPS · FY2025 | $22.87 | +5% y/y |
| Free Cash Flow · FY2025 | $6.34B | |
| Adjusted ROIC · FY2025 | 11.3% | |
| R&D Investment · FY2025 | $1.40B | |
| Share Repurchases · FY2025 | $3.00B | |
| GAAP Net Income · FY2025 | $6.70B | |
| Adjusted Net Income · FY2025 | $8.64B |
Risks flagged
Tariff and Trade Policy Risk
“Leveraged the PPI Business System to effectively navigate the new tariff and trade policy environment.” · word for word
Macroeconomic Uncertainty
“In the context of significant macroeconomic and operating uncertainty during 2025” · word for word
CEO Retention Risk
“The Board determined that securing his leadership through at least May 2030 was in the best interests of shareholders” · word for word
26 Feb 202610-KRevenue $44.56B (+4% y/y); GAAP operating income $7.75B (+6% y/y); Adjusted operating income $10.11B (+4% y/y); Guidance: Capex guided $1.8B-$2.0B for 2026; GAAP tax rate 7-9%; adjusted tax rate ~11.5%open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $44.56B | +4% y/y |
| GAAP operating income · FY2025 | $7.75B | +6% y/y |
| Adjusted operating income · FY2025 | $10.11B | +4% y/y |
| GAAP diluted EPS · FY2025 | $17.74 | +7% y/y |
| Adjusted EPS · FY2025 | $22.87 | +5% y/y |
| Free cash flow · FY2025 | $6.34B | -14% y/y |
| Operating cash flow · FY2025 | $7.82B | -10% y/y |
| Organic revenue growth · FY2025 | 2.0% | |
| Life Sciences Solutions revenue · Life Sciences Solutions · FY2025 | $10.37B | +8% y/y |
| Analytical Instruments revenue · Analytical Instruments · FY2025 | $7.55B | +1% y/y |
Guidance
Capex guided $1.8B-$2.0B for 2026; GAAP tax rate 7-9%; adjusted tax rate ~11.5%
No explicit revenue guidance; capex increase signals confidence; margin outlook stable with productivity offsetting headwinds.
Risks flagged
Tariff and FX margin pressure
“The decrease in segment income margin resulted primarily from the impacts of tariffs and related foreign exchange, strategic investments, and unfavorable business mix.” · word for word
China macro weakness
“Revenue to customers in the industrial and applied market grew. Revenues to customers in the diagnostics and healthcare market were flat. ... but declined in China.” · word for word
High debt level
“As of December 31, 2025, we had approximately $39.38 billion in outstanding indebtedness.” · word for word
COVID-related revenue headwind
“partially offset by reduced demand for COVID-19 vaccine and therapy related products and services.” · word for word
Academic funding uncertainty
“Revenues in the academic and government market declined, driven by customer hesitancy in a more uncertain environment in the U.S.” · word for word
12 Feb 20268-K · 1.01, 8.01Thermo Fisher issued notes raising ~$3.76B net proceeds to partially fund Clario acquisition; underwriting agreement with multiple banks.open
Figures in the filing · each found in the filing text
| Net proceeds from notes | $3.76B |
Risks flagged
Clario acquisition subject to regulatory approvals
“The Clario Acquisition is subject to the satisfaction of customary closing conditions, including the receipt of applicable regulatory approvals.” · word for word
29 Jan 20268-K · 2.02Revenue $12.21B (+7% y/y); GAAP diluted EPS $5.21 (+9% y/y); Adjusted EPS $6.57 (+8% y/y)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $12.21B | +7% y/y |
| GAAP diluted EPS · Q4-2025 | $5.21 | +9% y/y |
| Adjusted EPS · Q4-2025 | $6.57 | +8% y/y |
| Full year revenue · FY2025 | $44.56B | +4% y/y |
| Full year GAAP diluted EPS · FY2025 | $17.74 | +7% y/y |
| Full year adjusted EPS · FY2025 | $22.87 | +5% y/y |
| GAAP operating income · Q4-2025 | $2.26B | +12% y/y |
| Adjusted operating income · Q4-2025 | $2.88B | +6% y/y |
Risks flagged
Adjusted operating margin slightly compressed (23.6% vs 23.9%) despite revenue growth, indicating potential cost pressures or mix shift.
“Adjusted operating margin was 23.6%, compared with 23.9% in the fourth quarter of 2024.” · word for word
Heavy M&A activity ($13B committed) introduces integration risk and potential goodwill impairment.
“This included $13 billion committed to M&A. We completed the acquisition of ... and Sanofi’s Ridgefield ... announced a definitive agreement to acquire Clario.” · word for word
12 Jan 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Departure of COO and EVP may cause temporary leadership vacuum; restructuring could disrupt operations if not managed smoothly.
“Mr. Lagarde, who has served as Executive Vice President and Chief Operating Officer of the Company since 2021 will depart on March 31, 2026” · word for word
1 Dec 20258-K · 1.01, 8.01Net proceeds from notes 2,090,000,000open
Figures in the filing · each found in the filing text
| net proceeds from notes · Q4-2025 | $2.09B |
Risks flagged
Increased debt from note issuance may raise leverage, but proceeds intended for growth and refinancing.
“€2.09B notes issued; use of proceeds includes acquisition, debt repayment, and working capital.”
31 Oct 202510-QThermo Fisher reported Q3 2025 revenue of $11.122B (+5% YoY) and adjusted operating margin expansion of 100bps to 23.3%, driven by strong productivity and bioproduction demand.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $11.12B | +5% y/y |
| Net Income · Q3-2025 | $0.00 | |
| Free Cash Flow · Q3-2025 | $1.84B | -4% y/y |
| Operating Cash Flow · Q3-2025 | $2.24B | +3% y/y |
| Adjusted Operating Income Margin · Q3-2025 | 23.3% | |
| Life Sciences Solutions Revenue · Life Sciences Solutions · Q3-2025 | $2.59B | +8% y/y |
| Analytical Instruments Revenue · Analytical Instruments · Q3-2025 | $1.89B | +5% y/y |
| Specialty Diagnostics Revenue · Specialty Diagnostics · Q3-2025 | $1.17B | +4% y/y |
| Laboratory Products and Biopharma Services Revenue · Laboratory Products and Biopharma Services · Q3-2025 | $5.97B | +4% y/y |
| Adjusted EPS · Q3-2025 | $5.79 | +10% y/y |
Guidance
Capex guided $1.4B-$1.7B for FY2025; GAAP tax rate 8%-10%; adjusted tax rate ~10.5%
Management reaffirmed capex and tax rate guidance; margin expansion from productivity; demand mixed with pharma/biotech strong but academic/government and China weak.
Risks flagged
Tariff and FX Margin Pressure
“The decrease in segment income margin was driven by the impacts of tariffs and related foreign exchange.” · word for word
Academic & Government Market Weakness
“Revenues in the academic and government market declined, reflecting customer hesitancy in a more uncertain environment, which resulted in muted demand for equipment and instruments.” · word for word
China Revenue Decline
“Revenue to customers in the diagnostics and healthcare market declined as we navigated headwinds in China.” · word for word
29 Oct 20258-K · 8.01Acquisition consideration $8.88B; Deferred consideration $125M; Contingent consideration $400Mopen
Figures in the filing · each found in the filing text
| Acquisition consideration | $8.88B | |
| Deferred consideration | $125M | |
| Contingent consideration | $400M |
Risks flagged
Regulatory approval risk for acquisition
“subject to customary closing conditions and regulatory approvals” · word for word
Integration risk for large acquisition
“the parties being unable to successfully implement integration strategies or to achieve expected synergies and operating efficiencies” · word for word
Thermo Fisher Scientific Inc. — questions
- What did Thermo Fisher Scientific Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 8-K on 2026-10-21 — Revenue grew 9% to $12.14B, GAAP EPS $4.64 (+9%), adjusted EPS $6.68 (+15%), organic growth 6%. Guidance update deferred to call.
Every figure on this page comes from Thermo Fisher Scientific Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.